Cargando…

Conformational alteration in glycan induces phospholipase Cβ1 activation and angiogenesis

BACKGROUND: In endothelial cells, phospholipase C (PLC) β1-activated Ca(2+) is a crucial second messenger for the signaling pathways governing angiogenesis. PLCβ1 is inactivated by complexing with an intracellular protein called translin-associated factor X (TRAX). This study demonstrates specific i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sheng-Hung, Cheng, Jing-Yan, Tsai, Hsiu-Hui, Lo, Tzu-Chi, Hung, Jung-Tung, Lin, Chun-Cheng, Lee, Chien-Wei, Ho, Yi-Hsuan, Kuo, Huan-Hsien, Yu, Alice L., Yu, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753400/
https://www.ncbi.nlm.nih.gov/pubmed/36517806
http://dx.doi.org/10.1186/s12929-022-00889-w
_version_ 1784850955819286528
author Wang, Sheng-Hung
Cheng, Jing-Yan
Tsai, Hsiu-Hui
Lo, Tzu-Chi
Hung, Jung-Tung
Lin, Chun-Cheng
Lee, Chien-Wei
Ho, Yi-Hsuan
Kuo, Huan-Hsien
Yu, Alice L.
Yu, John
author_facet Wang, Sheng-Hung
Cheng, Jing-Yan
Tsai, Hsiu-Hui
Lo, Tzu-Chi
Hung, Jung-Tung
Lin, Chun-Cheng
Lee, Chien-Wei
Ho, Yi-Hsuan
Kuo, Huan-Hsien
Yu, Alice L.
Yu, John
author_sort Wang, Sheng-Hung
collection PubMed
description BACKGROUND: In endothelial cells, phospholipase C (PLC) β1-activated Ca(2+) is a crucial second messenger for the signaling pathways governing angiogenesis. PLCβ1 is inactivated by complexing with an intracellular protein called translin-associated factor X (TRAX). This study demonstrates specific interactions between Globo H ceramide (GHCer) and TRAX, which highlight a new angiogenic control through PLCβ1 activation. METHODS: Globo-series glycosphingolipids (GSLs), including GHCer and stage-specific embryonic antigen-3 ceramide (SSEA3Cer), were analyzed using enzyme-linked immunosorbent assay (ELISA) and Biacore for their binding with TRAX. Angiogenic activities of GSLs in human umbilical vein endothelial cells (HUVECs) were evaluated. Molecular dynamics (MD) simulation was used to study conformations of GSLs and their molecular interactions with TRAX. Fluorescence resonance energy transfer (FRET) analysis of HUVECs by confocal microscopy was used to validate the release of PLCβ1 from TRAX. Furthermore, the in vivo angiogenic activity of extracellular vesicles (EVs) containing GHCer was confirmed using subcutaneous Matrigel plug assay in mice. RESULTS: The results of ELISA and Biacore analysis showed a stable complex between recombinant TRAX and synthetic GHCer with Kd of 40.9 nM. In contrast, SSEA3Cer lacking a fucose residue of GHCer at the terminal showed ~ 1000-fold decrease in the binding affinity. These results were consistent with their angiogenic activities in HUVECs. The MD simulation indicated that TRAX interacted with the glycan moiety of GHCer at amino acid Q223, Q219, L142, S141, and E216. At equilibrium the stable complex maintained 4.6 ± 1.3 H-bonds. TRAX containing double mutations with Q223A and Q219A lost its ability to interact with GHCer in both MD simulation and Biacore assays. Removal of the terminal fucose from GHCer to become SSEA3Cer resulted in decreased H-bonding to 1.2 ± 1.0 by the MD simulation. Such specific H-bonding was due to the conformational alteration in the whole glycan which was affected by the presence or absence of the fucose moiety. In addition, ELISA, Biacore, and in-cell FRET assays confirmed the competition between GHCer and PLCβ1 for binding to TRAX. Furthermore, the Matrigel plug assay showed robust vessel formation in the plug containing tumor-secreted EVs or synthetic GHCer, but not in the plug with SSEA3Cer. The FRET analysis also indicated the disruption of colocalization of TRAX and PLCβ1 in cells by GHCer derived from EVs. CONCLUSIONS: Overall, the fucose residue in GHCer dictated the glycan conformation for its complexing with TRAX to release TRAX-sequestered PLCβ1, leading to Ca(2+) mobilization in endothelial cells and enhancing angiogenesis in tumor microenvironments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12929-022-00889-w.
format Online
Article
Text
id pubmed-9753400
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97534002022-12-16 Conformational alteration in glycan induces phospholipase Cβ1 activation and angiogenesis Wang, Sheng-Hung Cheng, Jing-Yan Tsai, Hsiu-Hui Lo, Tzu-Chi Hung, Jung-Tung Lin, Chun-Cheng Lee, Chien-Wei Ho, Yi-Hsuan Kuo, Huan-Hsien Yu, Alice L. Yu, John J Biomed Sci Research BACKGROUND: In endothelial cells, phospholipase C (PLC) β1-activated Ca(2+) is a crucial second messenger for the signaling pathways governing angiogenesis. PLCβ1 is inactivated by complexing with an intracellular protein called translin-associated factor X (TRAX). This study demonstrates specific interactions between Globo H ceramide (GHCer) and TRAX, which highlight a new angiogenic control through PLCβ1 activation. METHODS: Globo-series glycosphingolipids (GSLs), including GHCer and stage-specific embryonic antigen-3 ceramide (SSEA3Cer), were analyzed using enzyme-linked immunosorbent assay (ELISA) and Biacore for their binding with TRAX. Angiogenic activities of GSLs in human umbilical vein endothelial cells (HUVECs) were evaluated. Molecular dynamics (MD) simulation was used to study conformations of GSLs and their molecular interactions with TRAX. Fluorescence resonance energy transfer (FRET) analysis of HUVECs by confocal microscopy was used to validate the release of PLCβ1 from TRAX. Furthermore, the in vivo angiogenic activity of extracellular vesicles (EVs) containing GHCer was confirmed using subcutaneous Matrigel plug assay in mice. RESULTS: The results of ELISA and Biacore analysis showed a stable complex between recombinant TRAX and synthetic GHCer with Kd of 40.9 nM. In contrast, SSEA3Cer lacking a fucose residue of GHCer at the terminal showed ~ 1000-fold decrease in the binding affinity. These results were consistent with their angiogenic activities in HUVECs. The MD simulation indicated that TRAX interacted with the glycan moiety of GHCer at amino acid Q223, Q219, L142, S141, and E216. At equilibrium the stable complex maintained 4.6 ± 1.3 H-bonds. TRAX containing double mutations with Q223A and Q219A lost its ability to interact with GHCer in both MD simulation and Biacore assays. Removal of the terminal fucose from GHCer to become SSEA3Cer resulted in decreased H-bonding to 1.2 ± 1.0 by the MD simulation. Such specific H-bonding was due to the conformational alteration in the whole glycan which was affected by the presence or absence of the fucose moiety. In addition, ELISA, Biacore, and in-cell FRET assays confirmed the competition between GHCer and PLCβ1 for binding to TRAX. Furthermore, the Matrigel plug assay showed robust vessel formation in the plug containing tumor-secreted EVs or synthetic GHCer, but not in the plug with SSEA3Cer. The FRET analysis also indicated the disruption of colocalization of TRAX and PLCβ1 in cells by GHCer derived from EVs. CONCLUSIONS: Overall, the fucose residue in GHCer dictated the glycan conformation for its complexing with TRAX to release TRAX-sequestered PLCβ1, leading to Ca(2+) mobilization in endothelial cells and enhancing angiogenesis in tumor microenvironments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12929-022-00889-w. BioMed Central 2022-12-15 /pmc/articles/PMC9753400/ /pubmed/36517806 http://dx.doi.org/10.1186/s12929-022-00889-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Sheng-Hung
Cheng, Jing-Yan
Tsai, Hsiu-Hui
Lo, Tzu-Chi
Hung, Jung-Tung
Lin, Chun-Cheng
Lee, Chien-Wei
Ho, Yi-Hsuan
Kuo, Huan-Hsien
Yu, Alice L.
Yu, John
Conformational alteration in glycan induces phospholipase Cβ1 activation and angiogenesis
title Conformational alteration in glycan induces phospholipase Cβ1 activation and angiogenesis
title_full Conformational alteration in glycan induces phospholipase Cβ1 activation and angiogenesis
title_fullStr Conformational alteration in glycan induces phospholipase Cβ1 activation and angiogenesis
title_full_unstemmed Conformational alteration in glycan induces phospholipase Cβ1 activation and angiogenesis
title_short Conformational alteration in glycan induces phospholipase Cβ1 activation and angiogenesis
title_sort conformational alteration in glycan induces phospholipase cβ1 activation and angiogenesis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753400/
https://www.ncbi.nlm.nih.gov/pubmed/36517806
http://dx.doi.org/10.1186/s12929-022-00889-w
work_keys_str_mv AT wangshenghung conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT chengjingyan conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT tsaihsiuhui conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT lotzuchi conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT hungjungtung conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT linchuncheng conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT leechienwei conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT hoyihsuan conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT kuohuanhsien conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT yualicel conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis
AT yujohn conformationalalterationinglycaninducesphospholipasecb1activationandangiogenesis